Treatment of cerebrovascular disease with anticoagulants and platelet anti-aggregants;Tratamiento de la enfermedad cerebrovascular con anticoagulantes y antiagregantes plaquetarios

Revista de Neurologia

Volumn 29, Issue 12, 1999, Pages 1285-1290

  Ameriso, S F ^a,b,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b FLENI   (Argentina)

^c NONE   (Argentina)

Author keywords

Anti aggregant; Anticoagulant; Cerebral infarction; Cerebrovascular disease; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; TICLOPIDINE; WARFARIN;

ANTICOAGULANT THERAPY; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; SECONDARY PREVENTION; STROKE;

EID: 0033576522     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.2912.99348     Document Type: Conference Paper

References (64)

1. Sherman DG, Dyken ML, Gent M, Harrison MJG, Hart RG, Mohr JP. Antithrombotic therapy for cerebrovascular disorders: an update. Chest 1995; 108: S444-56.
2. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
3. Dyken ML. Meta-analysis in the assessment of therapy for stroke prevention. Cerebrovasc Dis 1992; 2 (Suppl 1): 35-40.
4. Caplan LR. Diagnosis and treatment of ischemic stroke. JAMA 1991; 266: 2413-8.
5. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Stroke 1993; 24: 35-41.
6. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. II. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
7. O'Brien JR. How much aspirin? Thromb Haemost 1990; 64: 486.
8. Akopov SS, Grigorian GS, Gabrielian ES. Dose-dependent aspirin hydrolysis and platelet aggregation in patients with atherosclerosis. J Clin Pharmacol 1992; 32: 133-5.
9. Hormes JT, Austin JH, James G, et al. Toward an optimal 'antiplatelet' dose of aspirin: preliminary observations. J Stroke Cerebrovasc Dis 1991; 1: 27-35.
10. Uchiyama S, Yamazaki M, Maruyama, S, et al. Shear-induced platelet aggregation and its inhibition by antiplatelet agents in cerebral ischemia. Clin Hemorheol 1993; 13: 623-36.
11. Uchiyama S, Yamazaki M, Maruyama S, et al. Shear-induced platelet aggregation in cerebral ischemia. Stroke 1994; 25: 1547-51.
12. Bernhardt J, Konstantin R, Luscher TF, et al. Acetylsalicylic acid, at high concentrations, inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol 1993; 21: 973-6.
13. Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 591-7.
14. The CATS Group. The Canadian-American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215-20.
15. Pryse-Phillips W. Ticlopidine Aspirin Stroke Study: outcome by vascular distribution of the qualifying event. J Stroke Cerebrovasc Dis 1993; 3: 49-56.
16. Grotta JC, Norris JW, Kamm TB, et al. Prevention of stroke with ticlopidine: who benefits most? Neurology 1992; 42: 111-5.
17. CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996; 348: 1329-39.
18. Álvarez Sabín J. Ácido acetilsalicílico y triflusal en la prevención del infarto cerebral aterotrombótico. Rev Neurol 1995; 23: 1091-5.
19. Jonas S. Anticoagulant therapy in cerebrovascular disease: review and meta-analysis. Stroke 1988; 19: 1043-8.
20. Rothrock JF, Hart RG. Antithrombotic therapy in cerebrovascular disease. Ann Intern Med 1991; 115: 885-95.
21. Feinberg WM, Albers GW, Barnett HJM, et al. Guidelines for the management of transient ischemic attacks. Stroke 1994; 25: 1320-33.
22. Matchar DB, McCrory DC, Barnett HJ, et al. Medical treatment for stroke prevention. Ann Intern Med 1994; 121: 41-53.
23. The Warfarin-Aspirin Recurrent Stroke Study (WARSS), The Antiphospholipid Antibodies and Stroke Study (APASS), The Patent Foramen Ovale in Cryptogenic Stroke Study (PICSS), The Hemostatic System Activation Study (HAS), The Genes in Stroke Study (GENESIS) Study. The feasibility of a collaborative double-blind study using an anticoagulant. Cerebrovasc Dis 1997; 7: 100-12.
24. Chimowitz MI, Kokkinos J, Strong J, Brown MB, Levine SR, Silliman S, et al. The Warfarin-Aspirin Symptomatic Intracranial Disease Study. Neurology 1995; 45: 1488-93.
25. Cerebral Embolism Task Force. Cardiogenic brain embolism: the second report of the Cerebral Embolism Task Force. Arch Neurol 1989; 46: 727-41.
26. Bogousslavsky J, van Melle G, Regli R, et al. Pathogenesis of anterior circulation stroke in patients with nonvalvular atrial fibrillation: The Lausanne Stroke Registry. Neurology 1990; 40: 1046-50.
27. Sandercock P, Bamford J, Dennis M, et al. Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long-term prognosis. Br Med J 1992; 305: 1460-5.
28. Martin R, Bogousslavsky J, for the Lausanne Stroke Registry Group. Mechanisms of late stroke after myocardial infarct. J Neurol Neurosurg Psychiatry 1993; 56: 760-4.
29. Tanne D, Goldbourt U, Zion M, et al. Frequency and prognosis of stroke/TIA among 4,808 survivors of acute myocardial infarction. Stroke 1993; 24: 1490-5.
30. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of longterm anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994; 1: 499-503.
31. Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980; 243: 661-9.
32. Cairns JA, Hirsh J, Lewis HD, et al. Antithrombotic agents in coronary artery disease. Chest 1992; 102 (Suppl): S456S-81.
33. Louie EK, Konstadt SN, Ras TLK, et al. Transesophageal echocardiographic diagnosis of patent foramen ovale in adults without prior stroke. Circulation 1991; 84 (Suppl 2): 451.
34. Hart RG. Cardiogenic embolism to the brain. Lancet 1992; 339: 589-94.
35. Amarenco P, Cohen A, Tzourio C, et al. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med 1994; 331: 1474-9.
36. Einhaupl KM, Villringer A, Meister W, Mehraein S, Garner C, Pellkofer M, et al. Heparin treatment in sinus venous thrombosis. Lancet 1991; 338: 597-600.
37. Saver JL, Easton JD, Hart RG. Dissections and trauma of cerebrocervical arteries. In Barnett HJM, Mohr JP, Stein BM, et al, eds. Stroke: pathophysiology, diagnosis and management. New York: Churchill-Livingstone; 1992. p. 670-88.
38. Hart RG, Kanter MC. 1990: Hematologic disorders and ischemic stroke: a selective review. Stroke 1990; 21: 1111-2.
39. Markus HS, Hambley H. Neurology and the blood: hematological abnormalities in ischemic stroke. J Neurol Neurosurg Psychiatry 1998; 64: 150-9.
40. Coull BM, Goodnight SH. Antiphospholipid antibodies, prethrombotic state, and stroke. Stroke 1990; 21: 1370-4.
41. Asherson RA, Khamashta MA, Ordi-ros J, et al. The 'primary' antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989; 68: 366-74.
42. Antiphospholipid Antibodies in Stroke Study (APASS) Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 1993; 43: 2069-73.
43. Antiphospholipid antibodies in Stroke Study Group (APASS). Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. Neurology 1997; 47: 91-4.
44. Levine SR. Antiphospholipid antibodies and the nervous system. Clinical features, mechanisms and treatment. Semin Neurol 1994; 14: 168-78.
45. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 14-5.
46. Ridker PM, Glynn RJ, Miletich JP, et al. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Intern Med 1997; 126: 528-31.
47. Thomas DP, Roberts HR. Hypercoagulability in venous and arterial thrombosis. Ann Intern Med 1997; 126: 638-44.
48. Mateo J, Oliver A, Borrell M, et al. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism. Results of the Spanish multicentric study on thrombophilia (EMET-Study). Thromb Haemost 1997; 77: 444-51.
49. Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
50. Kontula K, Ylikorkala A, Miettinen H, et al. Arg506Gln factor V mutation (factor V Leiden) in patients with ischemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 1995; 73: 558.
51. Press RD, Liu XY, Beamer N, et al. Ischemic stroke in the elderly. Role of the common factor V Leiden mutation causing resistance to activated protein C. Stroke 1996; 27: 44-8.
52. Adams HP Jr, Brott TG, Crowell RM, et al. Guidelines for the management of patients with acute ischemic stroke. A statement for health care professionals from a special writing group of the stroke council, American Heart Association. Stroke 1994; 25: 1901-14.
53. Sandercock PAG, van den Bolt AGM, Lindley RI, et al. Antithrombotic therapy in acute ischemic stroke. An overview of the completed randomized trials. J Neurol Neurosurg Psychiatry 1993; 56: 17-25.
54. Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke. A randomized trial. Stroke 1983; 14: 668-76.
55. Duke RJ, Bloch RF, Turpie AGG, et al. Intravenous heparin for the prevention of stroke progression in acute partial stable stroke. A randomized controlled trial. Ann Intern Med 1986; 105: 825-8.
56. Kay R, Wong KS, Yu YL, et al. Low molecular weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995; 333: 1588-92.
57. International Stroke Trial Collaborative Group. The International Stroke Trial (IST). A randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 1997; 349: 1569-81.
58. CAST (Chinese Acute Stroke Trial) Collaborative Group. Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997; 349: 1641-9.
59. The Publications Committee for the Trial of Org 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, Org 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. JAMA 1998; 279: 1265-72.
60. Bousser MG. Aspirin or heparin immediately after a stroke? Lancet 1997; 349: 1564-5.
61. Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. III. Reduction in venous thrombosis and pulmonary embolism of antiplatelet prophylaxis among surgical and medical patients. Br Med J 1994; 308: 235-46.
62. Turpie AGG, Gent M, Cote R, et al. A low-molecular weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. Ann Intern Med 1992; 117: 353-7.
63. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 144-52.
64. Franke CL, De Jonge J, van Swieten JC, et al. Intracerebral hematomas during anticoagulant treatment. Stroke 1990; 21: 726-30.